ACIU
AC Immune S.A.
NASDAQ · Healthcare · Biotechnology · CH
$2.86
−2.39%Margins
Gross margin
100.0%
EBITDA margin
-239.8%
EBIT margin
-252.3%
Net margin
-246.5%
FCF margin
-199.6%
-122.7%
Return on equity
-28.7%
Return on assets
-112.5%
Return on invested capital
0.12x
Asset turnover
-$43.1M
Cash from operations
$0.94
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026